NCT04920903 is a Phase 1 clinical trial of COR588 in Healthy Volunteers, sponsored by Cortexyme Inc..

Who is sponsoring NCT04920903?

NCT04920903 is sponsored by Cortexyme Inc..

What drugs are being tested in NCT04920903?

Interventions in NCT04920903: COR588, Placebo.

What condition does NCT04920903 study?

NCT04920903 studies Healthy Volunteers.

Is NCT04920903 still recruiting?

NCT04920903 is currently completed. Last updated 20 July 2022.

Last reviewed 2022-07-20 · How we verify

NCT04920903

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single and Multiple Ascending Dose Study of COR588

Completed Phase 1 Last updated 20 July 2022

What this trial tests

Phase 1 trial testing COR588 in Healthy Volunteers in 64 participants. Completed in 30 April 2022.

Timeline

26 August 2021

Primary endpoint
30 April 2022

30 April 2022

Quick facts

Lead sponsor	Cortexyme Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	64
Start date	26 August 2021
Primary completion	30 April 2022
Estimated completion	30 April 2022
Sites	1 location across Australia

Drugs / interventions tested

COR588 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Cortexyme Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety and tolerability of COR588 HCl in healthy male and female subjects.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2022.
Cummings J, Lee G, Nahed P, Kambar MEZN, et al · · 2022 · cited 369× · PMID 35516416 · DOI 10.1002/trc2.12295
Establishment of a consensus protocol to explore the brain pathobiome in patients with mild cognitive impairment and Alzheimer's disease: Research outline and call for collaboration.
Lathe R, Schultek NM, Balin BJ, Ehrlich GD, et al · · 2023 · cited 28× · PMID 37283269 · DOI 10.1002/alz.13076
Gingipain inhibitors as an innovative therapy for periodontal and associated-systemic diseases: a systematic review.
Pedrosa ME, Martin V, Fernandes MH, Gomes PS. · · 2025 · cited 7× · PMID 40839040 · DOI 10.1007/s00784-025-06472-5
Unraveling brain aging through the lens of oral microbiota.
Hu Q, Wang S, Zhang W, Qu J, et al · · 2025 · cited 5× · PMID 38993126 · DOI 10.4103/nrr.nrr-d-23-01761

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Cortexyme Inc. trials

Trials by the same sponsor.

NCT03823404 — GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease · Phase 2, PHASE3 · completed
NCT03418688 — A Multiple Ascending Dose Study of COR388 · Phase 1 · completed
NCT03331900 — Study of COR388 HCl in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04920903 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cortexyme Inc.
Last refreshed: 20 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04920903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing